openPR Logo
Press release

Acromegaly market expected to reach USD 3.2 billion by 2034

09-12-2025 10:39 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Acromegaly market

Acromegaly market

Acromegaly is a rare endocrine disorder caused by excess growth hormone (GH) secretion, typically due to a pituitary adenoma. It leads to progressive enlargement of bones and soft tissues, manifesting in facial changes, enlarged extremities, joint pain, and metabolic complications such as diabetes and cardiovascular disease.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71969

If untreated, acromegaly significantly reduces life expectancy and quality of life. Management includes surgical tumor removal, medical therapy (somatostatin analogs, GH receptor antagonists, dopamine agonists), and radiotherapy.

The global acromegaly market is expanding due to growing awareness, advances in diagnostics, new long-acting formulations, and orphan drug incentives supporting innovation.

Market Overview
• Market Size (2024): USD 1.8 billion
• Forecast (2034): USD 3.2 billion
• CAGR (2025-2034): 6.0%

Growth is supported by increasing early diagnosis rates, rising use of long-acting injectables, and clinical development of novel biologics and oral formulations.

Key Highlights:
• Prevalence estimated at 40-70 cases per million population worldwide.
• Delayed diagnosis (average 7-10 years) remains a challenge.
• Somatostatin analogs remain the cornerstone of medical therapy.
• New oral and depot formulations improving adherence.

Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Somatostatin Analogs (Octreotide, Lanreotide, Pasireotide)
o GH Receptor Antagonists (Pegvisomant)
o Dopamine Agonists (Cabergoline, Bromocriptine)
o Pipeline Agents (oral octreotide, long-acting depot formulations, novel receptor antagonists)

• Surgical Interventions
o Transsphenoidal Surgery (first-line for pituitary adenomas)
o Endoscopic Surgical Techniques (minimally invasive)

• Radiotherapy
o Conventional Radiotherapy
o Stereotactic Radiosurgery (Gamma Knife, CyberKnife)

• Diagnostics
o GH & IGF-1 Blood Testing
o MRI & CT Imaging of Pituitary Tumors

By Platform:
• Small Molecules (dopamine agonists)
• Biologics (somatostatin analogs, GH antagonists)
• Devices (surgical systems, imaging platforms)

By Technology:
• Long-Acting Injectable Formulations
• Oral Peptide Delivery Platforms
• MRI-Based Precision Imaging
• AI-Based Pituitary Tumor Detection

By End Use:
• Hospitals & Endocrinology Clinics
• Specialty Hormone & Rare Disease Centers
• Diagnostic Laboratories
• Research Institutes

By Application:
• Pituitary Adenoma-Associated Acromegaly
• Refractory Acromegaly (post-surgery/therapy)
• Clinical Research

Segmentation Summary:
Somatostatin analogs dominate therapy, but GH receptor antagonists and long-acting oral formulations are the fastest-growing categories. Surgery remains first-line, supported by precision imaging.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71969/acromegaly-market

Regional Analysis
North America
• ~42% share in 2024.
• High awareness, advanced endocrinology centers, and strong adoption of biologics.
• FDA approvals of long-acting and oral formulations driving growth.
Europe
• ~32% share.
• EMA approvals supporting lanreotide, pasireotide, and pegvisomant.
• Germany, UK, and France leading adoption of long-acting therapies.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.1%.
• Rising diagnosis rates in Japan, China, and India.
• Expanding access to biologics and rare disease funding.
Middle East & Africa
• Smaller share but improving access through orphan drug programs.
• Limited specialized endocrinology centers.
Latin America
• Brazil and Mexico leading adoption of generics and biologics.
• Expanding endocrinology care infrastructure.
Regional Summary:
North America and Europe dominate due to strong biologics adoption and infrastructure, while Asia-Pacific grows fastest due to increasing awareness and rare disease investments.

Market Dynamics
Key Growth Drivers:
• Rising global awareness and earlier diagnosis.
• Expanding use of long-acting and oral formulations.
• Growing rare disease funding and orphan drug incentives.
• Advances in minimally invasive pituitary surgery.

Key Challenges:
• Delayed diagnosis remains a major hurdle.
• High cost of biologics limiting access in low-resource regions.
• Long-term adherence challenges with injectables.
• Small patient pool limiting large-scale clinical trials.

Latest Trends:
• FDA and EMA approvals of oral octreotide capsules.
• Pipeline of novel long-acting depot formulations.
• Integration of AI-based MRI imaging for tumor detection and monitoring.
• Patient advocacy driving awareness and rare disease policy support.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71969

Competitor Analysis
Major Players in the Market:
• Novartis AG (Sandostatin, Signifor)
• Ipsen (Somatuline Depot)
• Pfizer Inc. (Somavert - Pegvisomant)
• Chiasma, Inc. (oral octreotide - Mycapssa, acquired by Amryt Pharma)
• Amryt Pharma plc
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd. (generics)
• Johnson & Johnson
• Merck KGaA
• GE Healthcare (MRI imaging for pituitary tumors)

Competitive Summary:
Novartis, Ipsen, and Pfizer dominate biologics. Amryt and Chiasma lead oral peptide delivery. GE drives diagnostic imaging. Competition is focused on novel formulations, long-acting biologics, and AI diagnostics.

Conclusion
The Acromegaly Market, valued at USD 1.8 billion in 2024, is projected to reach USD 3.2 billion by 2034, growing at a CAGR of 6.0%. Expansion of biologics, long-acting formulations, and precision diagnostics will shape the next decade of care.

Key Takeaways:
• Somatostatin analogs remain the cornerstone of treatment.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Oral and depot formulations improving adherence and accessibility.
• AI-driven imaging and minimally invasive surgery are redefining management.

The future of acromegaly care will move from delayed diagnosis and limited injectable options to precision diagnostics and multimodal long-acting therapies, creating opportunities for pharma, biotech, and medtech innovators.

This report is also available in the following languages : Japanese (アクロメガリー市場), Korean (말단비대증 시장), Chinese (肢端肥大症市场), French (Marché de l'acromégalie), German (Akromegalie-Markt), and Italian (Mercato dell'acromegalia), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71969/acromegaly-market#request-a-sample

Our More Reports:

Asia-Pacific Robotic Surgery Market
https://exactitudeconsultancy.com/reports/72335/asia-pacific-robotic-surgery-market

North America Robotic Surgery Market
https://exactitudeconsultancy.com/reports/72334/north-america-robotic-surgery-market

BRIC Gastric Bands and Balloons Market
https://exactitudeconsultancy.com/reports/72333/bric-gastric-bands-and-balloons-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acromegaly market expected to reach USD 3.2 billion by 2034 here

News-ID: 4180677 • Views:

More Releases from Exactitude Consultancy

Gonorrhea Market is expected to reach USD 3.6 billion by 2034.
Gonorrhea Market is expected to reach USD 3.6 billion by 2034.
Gonorrhea is a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, affecting the urogenital tract and throat. It is one of the most common bacterial STIs worldwide, with symptoms ranging from painful urination and discharge to infertility and systemic complications if untreated. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71965 The condition is a major public health threat due to rising antimicrobial resistance (AMR), as N. gonorrhoeae has developed resistance
Hyperphosphatemia Market to Reach USD 10.3 Billion by 2034
Hyperphosphatemia Market to Reach USD 10.3 Billion by 2034
Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated phosphate levels in the blood, most often associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). When kidneys fail to excrete phosphate efficiently, it accumulates, leading to vascular calcification, bone disorders, and increased cardiovascular risk. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71967 It remains a major complication in CKD and dialysis patients, making phosphate control a critical component
Alcohol-Related Liver Disease (ARLD) Market is expected to reach USD 17.9 billion by 2034
Alcohol-Related Liver Disease (ARLD) Market is expected to reach USD 17.9 billio …
Alcohol-related liver disease (ARLD) is a progressive liver condition caused by chronic and excessive alcohol consumption, encompassing a spectrum from steatosis (fatty liver) to alcoholic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71971 ARLD remains one of the leading causes of liver-related morbidity and mortality worldwide, driven by rising alcohol consumption, obesity, and metabolic syndromes. Early detection is difficult due to asymptomatic progression,
Cushing's disease market is expected to reach USD 1.1 billion by 2034
Cushing's disease market is expected to reach USD 1.1 billion by 2034
Cushing's disease is a rare endocrine disorder caused by excessive adrenocorticotropic hormone (ACTH) secretion, usually due to a pituitary adenoma. This leads to hypercortisolism (excess cortisol), resulting in symptoms such as weight gain, muscle weakness, diabetes, hypertension, osteoporosis, and psychiatric disturbances. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71973 If untreated, Cushing's disease significantly increases morbidity and mortality. Current treatment options include pituitary surgery, medical therapies targeting cortisol production or

All 5 Releases


More Releases for Acromegaly

Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market: Key F …
The Acromegaly Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Acromegaly Market Size During the Forecast Period? The market size for acromegaly has experienced swift expansion in the latest years. It is projected to rise from $2.15 billion in 2024 to $2.57
Acromegaly Global Market Report 2025: Surge in Acromegaly Cases Driving Market G …
Rapid growth is expected in the Acromegaly global market, driven by rising awareness, government initiatives, and demand for effective treatments. What Is The Projected Market Size Of The Global Acromegaly Global Market Report 2025 And Its Growth Rate? The acromegaly market size is set for considerable growth in the coming years. Key statistics include: • The market size grew from $2.15 billion in 2024 to an estimated $2.57 billion in 2025. • This represents
Exploring Acromegaly Treatment Market Growth
The global acromegaly treatment market is experiencing robust growth, with no signs of slowing down. In 2023, this market reached a significant milestone, boasting a total value of USD 1.61 billion. The future looks even more promising, with a projected compound annual growth rate (CAGR) of 7.65% from 2024 to 2032. By the end of this period, the market is expected to soar to approximately USD 3.12 billion. But what's
Acromegaly Market - Defeating Acromegaly, Restoring Lives
Newark, New Castle, USA: The "Acromegaly Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Acromegaly Market: https://www.growthplusreports.com/report/acromegaly-market/8421 This latest report researches the industry structure, sales, revenue, price and
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights. The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights. The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone